U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer Bayer announced that the U.S. Food and Drug Administration (FDA) has granted HYRNUO® (sevabertinib) Priority Review status for…
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead Turn Therapeutics Inc. a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, announced the appointment of Stephen M. Hahn,…
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing Scribe Therapeutics, Inc. a biotechnology company engineering purpose-built CRISPR technologies to reshape the treatment of disease by…
Bojangles Foundation Raises More Than $650,000 Through Heart-Shaped Biscuits & Round-Up Campaign to Support Pediatric Heart Care and Research For the second year in a row, Bojangles and The Bojangles Foundation partnered with NFL legend Greg Olsen and The HEARTest…
AVL Hosts Virtual Salon Suite Exploring How IVF Research Inspired a New Era of Science-Backed Skincare AV Laboratories, the science-backed skincare brand redefining the intersection of science, skincare, and longevity, will host an exclusive virtual salon suite on Thursday, May 21,…
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States ImmunityBio, Inc. a commercial-stage immunotherapy company, announced an exclusive U.S. Development and Supply Agreement with Japan BCG…
OBIO® and IPON Renew Multi-Year Collaboration to Advance Ontario’s Sovereign IP Capacity OBIO® and Intellectual Property Ontario (IPON) have renewed their memorandum of understanding (MOU) to ensure that Ontario’s next generation of companies developing innovative human health products continue to access optimal…
Massive Bio and Just Worldwide Announce Strategic Partnership to Connect More Cancer Patients to Clinical Trials Massive Bio, the global leader in AI-driven clinical trial matching for cancer patients, and Just Worldwide, a leading global fieldwork and market research provider…
IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic…
Next Health in Peoria Hosting Grand Opening, Bringing Advanced Longevity & Preventive Health Services to Arizona Next Health, the world’s most advanced and comprehensive brand of health optimization and longevity centers, invites the community and media to its newest location in…
Trinseo Takes Proactive Step to Strengthen Financial Foundation and to Drive Long-Term Sustainable Growth Trinseo PLC a specialty material solutions provider, announced that it entered into a Restructuring Support Agreement with parties that hold a majority of its debt. This…
Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC) Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, announced significant updates to two mission-driven initiatives:…